"As DEA rescheduling cases merge and federal hemp litigation moves to the D.C. Circuit, MMJ argues that companies following FDA rules should not be disadvantaged while non-FDA-approved cannabinoid products receive federal support" stated Duane Boise, CEO MMJ International Holdings.